BI 1569912
BI 1569912 is a selective modulator of the NMDA receptor. It is being developed by Boehringer Ingelheim to treat major depressive disorder.[1][2][3][4][5] As of 2023, it is in a Phase I trial.[6]
References[edit]
- ^ Just, Stefan; Ceci, Angelo; Ferger, Boris; Draheim, Henning; Giovannini, Riccardo; Rosenbrock, Holger; Dorner-Ciossek, Cornelia (May 2022). "P376. Preclinical Pharmacological Characterization of the Selective NR2b Negative Allosteric Modulator BI 1569912 With Potential to Treat MDD". Biological Psychiatry. 91 (9): S239. doi:10.1016/j.biopsych.2022.02.612.
- ^ Chen, Xiaowei; De Smedt, Heidi; Drevets, Wayne; Chen, Guang (May 2022). "P287. Data-Derived Subtypes of Treatment-Resistant Depression and Their Biomarker Correlates – A Pilot Study". Biological Psychiatry. 91 (9): S203–S204. doi:10.1016/j.biopsych.2022.02.523.
- ^ Brady, Linda S.; Lisanby, Sarah H.; Gordon, Joshua A. (2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555.
- ^ Schultheis, Christian; Hoch, Anja; Just, Stefan; Plano, Andrea (May 2022). "P285. Pharmacological Effects of the Novel NR2B Modulator Bi 1569912 on Electroencephalography and Eye-Tracking in a Phase I Study". Biological Psychiatry. 91 (9): S203. doi:10.1016/j.biopsych.2022.02.521.
- ^ Desch, Michael; Huennemeyer, Andreas; Süssmuth, Sigurd D. (2022). "P712. Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study". Biological Psychiatry. 91 (9): S379. doi:10.1016/j.biopsych.2022.02.949.
- ^ "BI-1569912 by Boehringer Ingelheim International for Major Depressive Disorder: Likelihood of Approval". Pharmaceutical Technology. 25 February 2023. Retrieved 4 November 2023.